IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Apollon Wealth Management LLC

Apollon Wealth Management LLC grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 9.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,874 shares of the medical research company’s stock after purchasing an additional 427 shares during the period. Apollon Wealth Management LLC’s holdings in IQVIA were worth $1,155,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in IQV. Keystone Financial Services acquired a new position in shares of IQVIA during the 3rd quarter valued at about $238,000. Versor Investments LP acquired a new stake in shares of IQVIA during the third quarter worth approximately $1,328,000. Jag Capital Management LLC lifted its stake in IQVIA by 2.1% during the third quarter. Jag Capital Management LLC now owns 12,431 shares of the medical research company’s stock worth $2,946,000 after purchasing an additional 259 shares during the last quarter. GDS Wealth Management lifted its stake in IQVIA by 8.0% during the third quarter. GDS Wealth Management now owns 54,893 shares of the medical research company’s stock worth $13,008,000 after purchasing an additional 4,056 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in IQVIA during the third quarter worth $57,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Down 4.1 %

Shares of NYSE:IQV opened at $202.94 on Friday. IQVIA Holdings Inc. has a 1 year low of $200.20 and a 1 year high of $261.73. The company has a market cap of $36.83 billion, a PE ratio of 26.63, a P/E/G ratio of 2.20 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock’s 50-day moving average is $228.86 and its 200 day moving average is $228.77.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 6.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Evercore ISI lowered their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. The Goldman Sachs Group reduced their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Barclays reduced their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, Argus upgraded IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $259.13.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.